Structure Therapeutics (NASDAQ:GPCR) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Structure Therapeutics (NASDAQ:GPCR) had its price target raised by analysts at Citizens Jmp from $87.00 to $120.00. They now have a "market outperform" rating on the stock.
Structure Therapeutics (NASDAQ:GPCR) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs [Yahoo! Finance]
Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional ADSs